Lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== 24-norursodeoxycholic acid === A recent scientific breakthrough for cholestasis that has allowed us to evaluate a new treatment option is that a hydrophilic environment and bicarbonate production protects hepatocytes from bile acid. The novel agent norUDCA (24-norursodeoxycholic acid) can be passively absorbed by cholangiocytes. This leads to bicarbonate production and an environment that is less toxic. Mouse models have found promising results with norUDCA with the drug showing antiproliferative and anti-inflammatory properties. A recent clinical trial found norUDCA had significant dose-dependent reductions for ALP levels. This makes norUDCA a viable possibility to look into as it clearly plays a significant role in the treatment of cholestasis.
=== 2007 === Reconstitution of a Cambodian traditional wood kiln 40 000 Litres. This kiln has mobilized 15 people for two months + 5000h work. The original kiln has been discovered at Phnom Kulen. 1st International Khmer Ceramics festival & Conference. The conference is held at the CKS center for Khmer study.
=== Implications in cancer development === There is a growing body of evidence supporting the role of GST, particularly GSTP, in cancer development and chemotherapeutic resistance. The link between GSTP and cancer is most obvious in the overexpression of GSTP in many cancers, but it is also supported by the fact that the transformed phenotype of tumor cells is associated with aberrantly regulated kinase signaling pathways and cellular addiction to overexpressed proteins. That most anti-cancer drugs are poor substrates for GSTP indicates that the role of elevated GSTP in many tumor cell lines is not to detoxify the compounds, but must have another purpose; this hypothesis is also given credence by the common finding of GSTP overexpression in tumor cell lines that are not drug resistant.
== History == April 2016: initiation of Phase 2b trial December 2017: initiation of JADE Mono-1 Phase 3 trial May 2018: Results of Phase 2b trial posted October 2019: Results of Phase 3 trial presented June 2020: Results of second Phase 3 trial published The US Food and Drug Administration (FDA) approved abrocitinib based on evidence from three controlled clinical trials enrolling a total of 1615 participants supporting efficacy and safety. Two of the trials enrolled participants twelve years of age and older with moderate-to-severe atopic dermatitis and one trial enrolled adults with moderate-to-severe atopic dermatitis. The trials were conducted at multiple sites in 18 countries (i.e., United States, Canada, Australia, Mexico, Chile, Great Britain, Poland, Germany, Bulgaria, Hungary, Czech Republic, Latvia, Slovakia, Spain, Italy, Japan, Korea, Taiwan). In addition, safety analyses were performed on the combined results of these 3 controlled clinical trials and one additional controlled study in a total of 1,540 participants. All three trials evaluated two doses of abrocitinib: 100 mg and 200 mg. The monotherapy trials were identically designed, 16-week, randomized, multicenter, double-blind, placebo-controlled, parallel group, phase 3 trials. Trial-AD-3 with concomitant background therapy was a 24-week, multicenter, randomized, double-blind, active-comparator (dupilumab) and placebo-controlled, phase 3 trial.
The gut of a starfish fills most of the central disc and extends into the arms. The mouth occupies the centre of the oral surface, where it is surrounded by a tough peristomial membrane and closed with a sphincter. A short oesophagus connects the mouth to a stomach, which consists of an eversible cardial portion and a smaller pyloric portion. The cardial stomach is glandular and pouched, and is supported by ligaments attached to ossicles in the arms so it can be pulled back into position after it has been everted. The pyloric stomach has two extensions into each arm: the pyloric caeca. These are long, hollow tubes lined by a series of glands which secrete digestive enzymes and absorb nutrients from the food. A short intestine and rectum run from the pyloric stomach to the anus at the apex of the aboral surface of the disc. Primitive starfish, such as Astropecten and Luidia, swallow their prey whole, and start to digest it in their cardial stomachs, spitting out hard material like shells. The semi-digested fluid flows into the caeca for more digestion as well as absorption. In more advanced species of starfish, the cardial stomach can be everted from the organism's body to engulf and digest food, which is passed to the pyloric stomach. The retraction and contraction of the cardial stomach is activated by a neuropeptide known as NGFFYamide. The main nitrogenous waste product is ammonia, which is removed via diffusion through the tube feet, papulae and other thin-walled areas. Other waste material include urates.
Sources: en.wikipedia.org
== Properties of the imidazole side chain == At neutral or physiological pH, the imidazole side chain is neutral. The imidazole side chain in histidine has a pKa of approximately 6.0. Thus, below a pH of 6, the imidazole ring is mostly protonated and carries a positive +1 charge (as described by the Henderson–Hasselbalch equation). The resulting imidazolium ring bears two NH bonds and has a positive charge. The positive charge is equally distributed between both nitrogen atoms and can be represented with two equally important resonance structures. Sometimes, the symbol Hip is used for this protonated form instead of the usual His. Above pH 6, one of the two protons is lost. The remaining proton of the imidazole ring can reside on either nitrogen atom, giving rise to what are known as the N3-H or N1-H tautomers. In the N1-H tautomer, the NH group is nearer the backbone. These neutral tautomers, also referred to as Nε (or Nτ, tau meaning tele — far) and Nδ (or Nπ, pi meaning pros — near), are sometimes referred to with symbols Hie and Hid, respectively. The imidazole/imidazolium ring of histidine is aromatic at all pH values. Under certain conditions, all three ion-forming groups of histidine can be charged forming the histidinium cation. The acid-base properties of the imidazole side chain are relevant to the catalytic mechanism of many enzymes. In catalytic triads, the basic nitrogen of histidine abstracts a proton from serine, threonine, or cysteine to activate it as a nucleophile. In a histidine proton shuttle, histidine is used to quickly shuttle protons.
=== Inherent instability of the enediyne core === The instability toward Bergman cyclization–reduction decomposition pathways poses a major threat to any proposed synthesis of enediynes. Myers and co-workers addressed this liability by late-stage dehydrative installation of the olefin. Without this unsaturation linking the two alkynyl bridges, synthetic intermediates are not disposed toward Bergman-type decomposition, and risk of decomposition is mitigated. In this case, dehydration of a propargylic alcohol was induced by treatment with Martin sulfurane.
== Heterotrophic versus autotrophic origin == The heterotrophic hypothesis, also known as the Oparin–Haldane hypothesis, proposes that the first organisms were heterotrophs that obtained energy and carbon from organic molecules accumulated through abiotic synthesis in the primitive environment. Alexander Oparin (1924) and J.B.S. Haldane (1929) independently argued that since heterotrophic anaerobes are metabolically simpler than autotrophs, heterotrophy must have evolved first. This concept traces back to Charles Darwin's 1871 speculation about life originating in "some warm little pond" containing ammonia, phosphoric salts, and energy sources where protein compounds could form. The Miller–Urey experiment (1953) provided experimental support by demonstrating abiotic synthesis of amino acids and other biochemically significant molecules under simulated early Earth conditions. The autotrophic hypothesis proposes that the earliest life forms were autotrophs capable of synthesizing organic molecules from inorganic carbon (CO2) using geochemical energy. Günter Wächtershäuser's iron–sulfur world theory suggests that life originated at hydrothermal vents where iron sulfide and nickel sulfide minerals catalyzed carbon fixation from volcanic gases. Experimental work demonstrated synthesis of activated acetic acid and peptide bond formation on (Fe,Ni)S surfaces under prebiotic conditions. The two hypotheses are not mutually exclusive; the FeS/H2S reducing chemistry central to autotrophic models is also consistent with heterotrophic scenarios.
Many were reported to not be wearing masks. Soon after, they dispersed. On 11 March, the number of people hospitalized hit a new record in Porto Alegre, with 800 people diagnosed to have COVID-19, and 43 suspected of being infected, and 187 awaiting beds. Even with this, Melo defended his administration in an interview published that day, businesses generally being open, then reduced by the state's decision to essential sectors. Due to the large increases in the number of deaths in the city, there were lines at the public records offices to register deaths, during which there waits of up to five hours, including during the early hours of the morning. The number of burials also increased. In total, the quantity of funerals in the city in March of that year was triple of those in March the prior year. The demand for cremations increased 63% during the middle of March 2021 in comparison with the first three months of the year prior for one crematorium. In another there was a 230% increase in cremations in comparison with March the year prior. Such was the amount of beds occupied that the waiting list for beds had grown to be days long. The overcrowding hit 116% on 15 March, with 1,204 people hospitalized with only 1,036 vacant beds. The waiting list would become 1270 people. At Hospital de Pronto Socorro, ran by the city, the overcrowding of beds led to 1,075% capacity. Various hospitals closed their emergency rooms because of the overcrowding of the units, including two of the largest in the city, Santa Casa and Clínicas.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.